Navigation Links
New Study Demonstrates that Lubiprostone May Improve Symptom Relief,Rates in Adults with Irritable Bowel Syndrome with Constipation,(IBS-C)

WASHINGTON, May 21, 2007 /PRNewswire/ -- A new study demonstrated that the active ingredient in Amitiza (lubiprostone), given 8 mcg twice a day, may improve symptom relief rates in adults with irritable bowel syndrome with constipation (IBS-C). These results were presented as a late-breaker at Digestive Disease Week 2007, the largest annual international meeting of digestive disease specialists.

"In this study, patients receiving lubiprostone were nearly twice as likely to achieve an overall response from symptoms of IBS-C compared to those receiving placebo," said Douglas A. Drossman, M.D., primary investigator, UNC Center for Functional GI and Motility Disorders, University of North Carolina, and the Chair of the Rome Committee. "As a result, lubiprostone may represent an important treatment for IBS-C sufferers."

IBS is a condition that affects approximately 58 million Americans and accounts for 25-50 percent of referrals to gastroenterologists. IBS-C symptoms include abdominal pain or discomfort associated with defecation or a change in bowel habits with features of disordered defecation.

Lubiprostone is a novel selective chloride channel activator that has been shown to be effective and well-tolerated in a number of well-controlled clinical trials in patients with chronic idiopathic constipation. Lubiprostone is marketed in the U.S. as AMITIZA, a 24-mcg gelcap that was approved for use for chronic idiopathic constipation in adults on January 31, 2006.

Sucampo Pharmaceuticals expects to submit a supplemental New Drug Application for IBS-C to the U.S. Food and Drug Administration by July 2007.

About the Study for IBS-C (lubiprostone 8 mcg)

In two phase III, multi-center, double-blind, randomized, placebo- controlled trials, 1,171 adults diagnosed with IBS-C (Rome II Criteria) were enrolled and received lubiprostone 8 mcg taken twice daily (783 adults) or placebo (388
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:8/29/2014)... N.C. , Aug. 29, 2014 The ... of regulatory and marketplace changes. CI leaders who adjust ... In a new Best Practices, LLC study ... of actionable insights, including: - Use secondary ... than primary research - Internal staff who ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 /PRNewswire/ ... Medina Medical as CEO and member of the Board ... three decades of medical device development and commercialization experience, ... Medical,s field. Mr. Engelson previously served as a Partner ... served as President and CEO of two Foundry start-ups. ...
(Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2US CNS Disorders Drug Pipeline Insight 2014 2
... 23 SurgiCount Medical, the wholly-owned operating subsidiary ... PSTX ), announced that results of ... Clinic on their multi-year effort to reduce retained ... two upcoming conferences.  The research and related discussion ...
... Agreement to Develop and... -- ABBOTT PARK, Ill. and IRVING, Texas, Sept. 23 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:Mayo Clinic Research on SurgiCount To Be Presented at Conferences 2Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 2Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 3Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 4Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 5Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 6Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 7Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 8Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 9
(Date:8/29/2014)... August 29, 2014 As reported by WKMS.com ... Recovery , an Ohio municipal court drug has come up ... Fred Moses, who serves as the presiding judge in a ... makers to offer addicts a medicated treatment option that can ... the drug known as Vivitrol, which blocks receptors in the ...
(Date:8/29/2014)... 29, 2014 According to new research presented ... Peer Pressure, Key to Prescription Drug Misuse Among Young Adults ... for 18-29 year olds when it comes to prescription drug ... this age group the real problem which influences misuse of ... and recreational use of them to have fun with other ...
(Date:8/29/2014)... Dallas, Texas (PRWEB) August 30, 2014 ... Glass microfiber Industry, 2009-2019 is a professional and ... microfiber industry. The report firstly reviews the basic ... and manufacturing technology. The report then explores global ... their product specification, capacity, Production value, and market ...
(Date:8/29/2014)... 2014 Healthpointe has unveiled its new ... the convenience of visiting with physicians online. Anyone can ... , Healthpointe doctors are always available and happy to ... the doctor can even see the patient’s entire family. ... or she can prescribe medications that are available for ...
(Date:8/29/2014)... August 29, 2014 Healthpointe is ... University Physical Therapy students via Clinical Rotations. ... will be shadowing Healthpointe providers and specialists throughout ... to develop clinical experience and learn professional preparation. ... will gain insight into several patient care techniques ...
Breaking Medicine News(10 mins):Health News:Ohio Judge Pushes for Addiction Recovery Tool 2Health News:Ohio Judge Pushes for Addiction Recovery Tool 3Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 2Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Virtual Doctor’s Appointments Now Available at Healthpointe 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2
... , BOYNTON BEACH, Fla. , Feb. ... of this year,s US Open Men,s and Women,s tennis tournament ... http://www.newscom.com/cgi-bin/prnh/20100209/DC52484 ) , (Logo: http://www.newscom.com/cgi-bin/prnh/20100120/DC41252LOGO-b ) , Would you ... Golf tournament, complete with airfare and accommodations? , Would you ...
... INDIANAPOLIS -- In the first large-scale epidemiological study of ... researchers from the Indiana University School of Medicine and ... 2010 issue of The Journal of Trauma Injury, ... and opportunities for prevention of these injuries. Nearly ...
... Medical Center are offering pediatric patients diagnosed with chronic ... negative side effects like nausea, fatigue, and vomiting caused ... confluence of Chinese and Western medicine at Rush Children,s ... document how acupuncture might help in reducing pain in ...
... ... Collection Manager™ increases patient safety through accuracy and timeliness , ... (PRWEB) February 9, 2010 ... outreach solutions, announced today that the University of Virginia Health System Medical Laboratories, ...
... D begins in the womb, expert says, , TUESDAY, Feb. ... lots of milk and have a high dietary intake of ... developing multiple sclerosis later in life, researchers say. , The ... about their experiences and diet during pregnancy. The nurses were ...
... , Consumer Watchdog Also Warns Against Insurer-favored ,Cost Solution,: ... Apartment" , WASHINGTON , Feb. 9 ... its premium hikes of up to 39% in California , ... House and an investigation by California ,s insurance commissioner, federal ...
Cached Medicine News:Health News:Would You Like to Own a Thriller Album Autographed by Michael Jackson Himself? 2Health News:Watch your step: Elevator-related injuries and older adults 2Health News:Watch your step: Elevator-related injuries and older adults 3Health News:Young patients with chronic illnesses find relief in acupuncture 2Health News:University of Virginia Health System Medical Laboratories Selects Sunquest's Specimen Collection Solution 2Health News:University of Virginia Health System Medical Laboratories Selects Sunquest's Specimen Collection Solution 3Health News:Drinking Milk While Pregnant May Lower Kids' MS Risk 2Health News:Blue Cross Claim That 39% Premium Hikes Due Only to 'Escalating Cost of Health Care' Trigger Calls for Regulation of Rates 2Health News:Blue Cross Claim That 39% Premium Hikes Due Only to 'Escalating Cost of Health Care' Trigger Calls for Regulation of Rates 3
One channel transcranial Doppler...
Flagship Transcranial Doppler system with multiple channel options, multi-depth options....
Swiss Watchmaker Forceps, 4" extra-long precision ground points....
... fine tips and are intended for the most ... The curved ones are ideal for tweezing out ... student versions are for beginners. These Dumont/Swiss watchmaker ... The Swiss forceps are made from the highest ...
Medicine Products: